A new angle on one of cancer's hardest problems
Researchers at the University of Alberta have identified a potential way to interfere with how glioblastoma spreads through the brain, offering a promising lead against one of the deadliest and most treatment-resistant cancers. Their study, published in Neuro-Oncology, focuses on the structures glioblastoma cells use to move, connect, and resist therapy.
Glioblastoma is an aggressive brain cancer with average survival commonly measured in months rather than years. According to the source text, it affects about 4 in 100,000 people and is associated with average survival of 12 to 18 months. Its lethality is not just a matter of tumor growth. A major challenge is infiltration: cancer cells extend into surrounding brain tissue, making full removal difficult and recurrence common.
Tumor microtubes and the machinery of invasion
The Alberta team studied long cellular protrusions known as tumor microtubes. These structures form a fiber-like network that helps glioblastoma cells invade new areas of the brain. They have also been linked to resistance against radiotherapy and chemotherapy, making them especially important targets.
Using human cell cultures and mouse models, the researchers examined what enables those microtubes to form. Their work points to FABP7, a brain fatty acid-binding protein that normally plays a role during brain development. In the developing brain, FABP7 helps neural stem cells build fiber networks that guide migrating neurons to their proper destinations.
The study suggests glioblastoma is reusing that developmental program. FABP7 appears to be overexpressed in glioblastoma and re-expressed in tumor microtubes, effectively giving cancer cells access to a migration system that resembles the one used during normal brain formation.
What happened when FABP7 was blocked
The most important result is what happened when researchers chemically inhibited FABP7. In cellular experiments, the intervention prevented the formation of tumor microtubes, reduced tumor migration, and increased sensitivity to temozolomide, a standard chemotherapy drug used in glioblastoma treatment.
The mouse data strengthened the case. Mice with glioblastoma that received the FABP7 inhibitor lived significantly longer than animals in the control group, according to the source text. That does not make the approach ready for clinical use, but it does move the idea beyond a purely mechanistic observation.
In practical terms, the findings suggest that targeting FABP7 could affect several of glioblastoma's most damaging traits at once: its ability to spread, its physical networking behavior, and its resistance to existing therapy.
Why this could matter clinically
The current standard of care for glioblastoma still struggles against recurrence and diffuse invasion. A treatment that makes tumor cells less mobile and more vulnerable to chemotherapy would be significant even if it does not cure the disease on its own. The value here may lie in combination use rather than in a standalone drug.
The research team is already testing that idea. The Godbout laboratory is exploring whether FABP7 inhibition works effectively alongside temozolomide or radiotherapy in a larger cohort of mice. That next step matters because glioblastoma treatment is inherently multimodal, and any new agent will likely need to prove its value in combination with established approaches.
There is still a long road from animal results to patient benefit. Safety, dosing, delivery into brain tissue, and durability of response all remain open questions. But the study offers something that glioblastoma research badly needs: a concrete biological handle on the disease's invasive behavior.
If further work holds up, FABP7 could emerge as more than a marker of tumor aggression. It could become a therapeutic target aimed at the structural logic glioblastoma uses to outrun surgery, radiation, and chemotherapy. For a cancer defined by relentless spread, disrupting that logic is a meaningful advance.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
